Finance

Lists
X2S:FRA
Sinopharm Group Co Ltd
€1.73
-1.20%
(-0.021) 1D
Aug 28, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for X2S...
Open
€1.73
High
€1.73
Low
€1.73
Mkt. cap
49.71B
Avg. vol.
1.58K
Volume
0.00
52-wk high
€2.37
52-wk low
€1.69
No. of employees
90K
Open
€1.73
High
€1.73
Low
€1.73
Mkt. cap
49.71B
Avg. vol.
1.58K
Volume
0.00
52-wk high
€2.37
52-wk low
€1.69
No. of employees
90K
Profile
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical. Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted. Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
About Sinopharm Group Co Ltd
CEO-
Employees90.4K
Founded2003
Headquarters-
SectorHealth care provider
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
145.44B
143.69B
140.77B
142.03B
Cost of goods sold
134.52B
133.28B
131.40B
132.33B
Cost of revenue
134.52B
133.28B
131.40B
132.33B
Research and development expenses
172.61M
-172.61M
46.59M
-46.59M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.17B
7.34B
5.10B
5.70B
Operating expense
6.80B
5.00B
6.29B
5.43B
Total operating expenses
141.32B
138.29B
137.69B
137.76B
Operating income
4.12B
5.40B
3.07B
4.28B
Other non operating income
120.78M
-427.44M
39.60M
-118.14M
EBT including unusual items
3.67B
3.92B
2.90B
4.05B
EBT excluding unusual items
3.51B
5.36B
2.90B
4.25B
Income tax expense
905.42M
1.19B
712.28M
1.05B
Effective tax rate
24.66%
30.30%
24.57%
26.02%
Other operating expenses
917.07M
-1.10B
204.49M
-392.73M
Net income
1.84B
1.85B
1.41B
1.99B
Net profit margin
1.27%
1.29%
1.00%
1.40%
Earnings per share
-
-
-
-
Interest and investment income
364.24M
-
171.27M
-
Interest expense
-412.56M
-846.59M
-383.82M
-505.78M
Net interest expenses
-48.32M
-846.59M
-212.55M
-505.78M
Depreciation and amortization charges
-
-
-
-
EBITDA
4.66B
5.91B
3.58B
4.78B
Gain or loss from assets sale
11.79M
-20.53M
-
-
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google apps